Literature DB >> 21369960

Prescribing pattern of antihypertensive drugs in a general hospital in central China.

Hong Cheng1.   

Abstract

OBJECTIVES: To examine the prescribing pattern of antihypertensive drugs in outpatients with hypertension in a general hospital in central China and identify whether the pattern of prescribing is appropriate and in accordance with national and international guidelines for pharmacotherapy of hypertension.
SETTING: The internal medicine department of Zhongnan Hospital in central China.
METHOD: Antihypertensive prescription data were collected from the hospital's central computer database from 1 March 2008 to 31 March 2008. MAIN OUTCOME MEASURE: The most frequently used antihypertensive medications, as a percentage of treatment and of monotherapy or combination therapy.
RESULTS: 1,206 prescriptions were included in the analysis. The mean age of the patient population was 61.3 ± 13.7 years and 68.6% were male. The mean number of drugs used by the patient was 1.45 ± 0.66. Of the patients, 62.9% were receiving monotherapy, 29.4% two drugs, 6.9% three drugs, and 0.8% four drugs. Most patients were receiving calcium channel blockers (58.0%), followed by angiotensin receptor blockers (34.2%), angiotensin-converting enzyme inhibitors (17.5%), beta-blockers (16.9%) and diuretics (16.7%).
CONCLUSION: This study showed that most outpatients with hypertension in our hospital received monotherapy although national and international guidelines indicated that monotherapy achieves the BP target in only a limited number of hypertensive patients. We also found that the most frequently used class of antihypertensive drugs was calcium channel blockers then angiotensin receptor blockers. Despite the various benefits of diuretics, they remain underutilized. Moreover, calcium channel blockers were used most frequently in hypertensive patients with comorbidities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21369960     DOI: 10.1007/s11096-010-9476-8

Source DB:  PubMed          Journal:  Int J Clin Pharm


  17 in total

1.  Physicians and the pharmaceutical industry: is a gift ever just a gift?

Authors:  A Wazana
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

3.  Antihypertensive drug prescribing in Grampian.

Authors:  Sarah Ross; Mary Joan Macleod
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

4.  [Current status of primary hypertension in China: an epidemiological study of 12 provinces, 1 autonomous regions, and 1 municipality].

Authors:  Xiu-li Zhao; Jie Chen; Yan-li Cui; Feng Wu; Da-yi Hu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2006-04-25

5.  [Economic burden of coronary heart disease and stroke attributable to hypertension in China].

Authors:  Yi Zhai; Jian-Ping Hu; Ling-Zhi Kong; Wen-Hua Zhao; Chun-Ming Chen
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2006-09

6.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

7.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan.

Authors:  Pang-Hsiang Liu; Jung-Der Wang
Journal:  BMC Health Serv Res       Date:  2008-06-18       Impact factor: 2.655

View more
  3 in total

1.  The healthcare burden of hypertension in Asia.

Authors:  Chun-Na Jin; Cheuk-Man Yu; Jing-Ping Sun; Fang Fang; Yong-Na Wen; Ming Liu; Alex Pui-Wai Lee
Journal:  Heart Asia       Date:  2013-11-19

Review 2.  Systolic hypertension: an increasing clinical challenge in Asia.

Authors:  Jeong Bae Park; Kazuomi Kario; Ji-Guang Wang
Journal:  Hypertens Res       Date:  2014-12-11       Impact factor: 3.872

3.  Prescribing trend in cardiovascular patients at Ethiopian university hospital: The number of medications and implication on the clinical improvement.

Authors:  Yonas G Tefera; Tamrat B Abebe; Abebe B Mekuria; Misganaw S Kelkay; Tadesse M Abegaz
Journal:  Pharmacol Res Perspect       Date:  2019-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.